Impact of preimplantation genetic testing for aneuploidy (PGT-A) on gestational carrier (GC) cycles in the United States

Abstract

DESIGN: prospective randomized controlled trial. MATERIALS AND METHODS: A total of 60 low responder, who were defined as patient who failed to produce <3 follicles with a mean diameter of < 16 mm with the result that <3 oocytes were retrieved despite the use of a high gonadotropin dose in a previous failed IVF/ICSI cycle from 1.1.18 to 31.3.19 (15 months). Patient were randomized into TTG pretreatment group and control group. For TTG pretreatment group, 12.5mg TTG were applied daily for 21 days in the cycle preceding COS for IVF.RESULTS: There were no differences in patients characteristics between the two group. Total dose of FSH used were significantly fewer in the TTG pretreatment group than in the control group. The number of oocytes retrieved , mature oocytes, fertilized oocytes, and good quality embryos were significantly higher in the TTG pretreatment group. Embryos implantation rate and clinical pregnancy rate per cycle also were significantly higher in the women pretreated with TTG. No patient reported adverse effects attributed to TTG use.CONCLUSIONS: TTG pretreatment might be beneficial in improving both response to COS and IVF outcome in low responders undergoing IVF/ICSI. (fertil steril 2011;95:679-83. 2011 by American society for reproductive medicine).